Foghorn Therapeutics Inc. (FHTX)
| Market Cap | 419.85M +41.2% |
| Revenue (ttm) | 36.74M +52.0% |
| Net Income | -64.58M |
| EPS | -0.97 |
| Shares Out | 59.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 536,547 |
| Open | 7.10 |
| Previous Close | 7.01 |
| Day's Range | 6.95 - 7.35 |
| 52-Week Range | 3.27 - 7.61 |
| Beta | 2.83 |
| Analysts | Strong Buy |
| Price Target | 11.44 (+61.81%) |
| Earnings Date | Aug 6, 2026 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leuk... [Read more]
Financial Performance
In 2025, Foghorn Therapeutics's revenue was $30.91 million, an increase of 36.75% compared to the previous year's $22.60 million. Losses were -$74.28 million, -14.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price target is $11.44, which is an increase of 61.81% from the latest price.
News
Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)
Reports Q2 revenue $16.07M, consensus $7.93M. “Our FHD-909 trial in collaboration with Lilly continues to advance through dose escalation, with an initial focus on SMARCA4-mutant NSCLC, a setting wher...
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat mu...
Foghorn Therapeutics Quarterly report: Q2 2026
Foghorn Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Foghorn Therapeutics Earnings release: Q2 2026
Foghorn Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Foghorn Therapeutics Slides: Investor presentation
Foghorn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, P...
Foghorn Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
FHD-909, a selective SMARCA2 inhibitor for NSCLC, is nearing a key expansion decision with Eli Lilly in summer 2026, supported by a robust proprietary pipeline targeting oncology and autoimmune indications. Cash runway extends into H1 2028, with further funding needed for broader clinical development.
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
Reports Q1 revenue $3.27M, consensus $7.94M. “Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA...
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memor...
Foghorn Therapeutics Quarterly report: Q1 2026
Foghorn Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Foghorn Therapeutics Earnings release: Q1 2026
Foghorn Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Foghorn Therapeutics Slides: Investor presentation
Foghorn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Foghorn Therapeutics Proxy statement: Proxy filing
Foghorn Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Foghorn Therapeutics Proxy statement: Proxy filing
Foghorn Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Foghorn Therapeutics presents new preclinical data for FHD-909
Foghorn Therapeutics (FHTX) presented new preclinical data for Selective SMARCA2 inhibitor FHD-909 showing complete and durable tumor regression together with anti-tumor immune memory following combin...
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Foghorn Therapeutics Annual report: Q4 2025
Foghorn Therapeutics has published its Q4 2025 annual report on March 11, 2026.
Foghorn Therapeutics Earnings release: Q4 2025
Foghorn Therapeutics released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Foghorn Therapeutics Slides: Investor presentation
Foghorn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The pipeline features advanced protein degrader programs in oncology, with key assets progressing toward IND-enabling studies and a major partnered SMARCA2 program in dose escalation. Financial strength was bolstered by a recent $50 million offering, supporting ongoing R&D and clinical milestones.
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...